The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older

Last updated: December 5, 2024
Sponsor: University of Illinois at Chicago
Overall Status: Active - Recruiting

Phase

N/A

Condition

Obesity

Metabolic Syndrome

Circulation Disorders

Treatment

Augmented Intervention

Base intervention

Clinical Study ID

NCT05654142
2022-1230
  • Ages 50-74
  • All Genders

Study Summary

This is a multisite clinical trial of healthy lifestyle programs for middle-to-older-aged adults (50 -74 years) to improve their weight and, therefore, reduce risk for chronic disease. This study will investigate whether a proven, self-directed video-based lifestyle program can be significantly enhanced with the assistance of a coach via videoconference or phone to help people as they adopt healthy eating and exercise behaviors. Additionally, the study will examine what factors might explain why some people achieve better outcomes than others. Understanding this can help to tailor the program to an individual for personalized care in the future.

Importantly, this study aims to demonstrate how readily a digital lifestyle program, with or without remote coaching, can be seamlessly delivered to patients at home via the patient portal of their electronic health record. This practical use of existing telehealth tools could be a feasible and effective means to offer behavioral treatments during routine medical care.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 50 - 74 years (inclusive)

  • Confirmed body mass index (BMI) ≥27.0 based on:

  • Weight measured by participant at home using the study-provided wireless weightscale

  • Height documented in the EHR during at least 2 separate ambulatory careencounters within the past 2 years

  • Diagnosis of 1 or more cardiometabolic condition (prediabetes, metabolic syndrome,type 2 diabetes, hypertension, dyslipidemia) in the EHR

  • Willing and able to accept randomization, and provide written informed consent andHIPAA authorization

  • Willing and able to participate in all aspects of the data collection andintervention protocols, including remote monitoring with a study-provided wirelessweight scale and activity tracker and the use of a study tablet for access ofMyChart, REDCap, and Fitbit apps

Exclusion

Exclusion Criteria:

  • Unable to speak, read, understand English sufficiently for informed consent

  • No reliable Wi-Fi Internet access at home

  • Self-report of current active weight loss treatment, including research-basedcommercial weight loss programs (e.g., Weight Watchers, Jenny Craig, HMR, Omada,TOPS), other weight loss or related behavioral health or wellness programs led bytrained personnel (professional or lay) at the recruiting clinic or in the localcommunity, and prescription weight loss medications

  • Screen positive for active eating disorder (bulimia nervosa or binge eatingdisorder) using PHQ- eating disorder module

  • Planned or prior bariatric surgery within the last 2 years (Note: patients who aremore than 2 years post bariatric surgery can participate if otherwise eligible)

  • Unable to pass the Revised Physical Activity Readiness Questionnaire (PAR-Q) orobtain physician medical clearance to participate

  • Presence of any significant safety concerns or contraindications related to seriousphysical or mental health issues based on the EHR or self-report (e.g., type 1diabetes or insulin dependence, myocardial infarction, stroke, cancer diagnosis (other than non-melanoma skin cancer) within the past 12 months and/or activelyreceiving cancer treatment, end-stage organ failure, bipolar disorder, psychosis,life expectancy <12 months)

  • Cognitive impairment based on the Callahan 6-item screener

  • Active alcohol or substance use disorder (including prescription drugs) based on theCAGE Questionnaire Adapted to Include Drugs (CAGE-AID)

  • Discontinued health care at the recruiting site, or plan to discontinue in the next 12 months

  • Participation in other behavioral, medical or surgical treatment studies byself-report that conflict with the primary weight loss outcome of this study.

  • Family/household member of an already enrolled participant or of a study team member

  • Investigator discretion for clinical safety or protocol adherence reasons

Study Design

Total Participants: 1029
Treatment Group(s): 2
Primary Treatment: Augmented Intervention
Phase:
Study Start date:
April 17, 2023
Estimated Completion Date:
October 31, 2026

Study Description

This multisite clinical trial uses a 2-stage sequential randomization design to test the adaptive and nonadaptive augmentation of a validated Group Lifestyle Balance (GLB) video program (base intervention) using problem solving treatment (PST), a proven behavior therapy. The GLB video program will be delivered via the patient portal of the electronic health record system. Trained coaches will deliver PST remotely via videoconference or phone.

English-speaking adults (N=1029), 50-74 years of age with a body mass index ≥27 and ≥1 cardiometabolic conditions, will be randomized at baseline to base intervention or waitlist control. Participants initially randomized to the waitlist control will be re-randomized after a 12-week control period to receive the base (Group A) or the augmented intervention (Group B), without tailoring based on early weight loss. Among participants initially randomized to the base intervention, responders defined by ≥3% weight loss at 6 weeks will continue the base intervention (Group C); nonresponders who are participants with <3% weight loss or missing weight data by 6 weeks will be re-randomized to continue the base intervention alone (Group D) or augmented with PST coaching via videoconference (Group E).

We hypothesize: (1) the augmented intervention will be more effective than the base intervention both among early nonresponders to the base intervention (adaptive) and among participants in the waitlist control condition (nonadaptive) at 52 weeks; (2) the adaptive augmented intervention will be more efficacious than the base intervention and more efficacious than the waitlist control condition at 12 weeks. Aim 2 is to identify predictors of clinically significant (5%) weight loss for individual patients, using sociodemographic, clinical and behavioral engagement characteristics.

Connect with a study center

  • Department of Medicine, Vitoux Program on Aging and Prevention

    Chicago, Illinois 60608
    United States

    Active - Recruiting

  • Washington University School of Medicine in St Louis

    Saint Louis, Missouri 63110
    United States

    Active - Recruiting

  • University of Pittsburgh School of Medicine

    Pittsburgh, Pennsylvania 15213
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.